Form 4: Twist Bio CEO Emily Leproust Acquires 168,976 Shares
Insider Transaction Report
Twist Bioscience CEO Emily Leproust acquired 168,976 shares of common stock through the vesting of performance stock units.
Summary
- Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corp (TWST), acquired 168,976 shares of common stock.
- The acquisition occurred on October 28, 2025, and resulted from the vesting of Performance Stock Units (PSUs).
- The target criteria for these PSUs were determined to have been met on October 28, 2025.
- 60% of these PSUs remain subject to time-based vesting and will vest on October 1, 2026, contingent on continued service.
- Following this transaction, Ms. Leproust directly beneficially owns 770,188 shares of Twist Bioscience common stock.
- The filing also details several existing employee stock options with various exercise prices and vesting schedules, none of which were transacted in this report.
Sentiment
Score: 7
Explanation: The vesting of performance stock units indicates that the company's CEO met specific performance targets, which is generally a positive sign for company performance and executive alignment. This is a routine, positive event for the executive and reflects well on the company's ability to meet its internal goals.
Positives
- CEO Emily M. Leproust met performance criteria for 168,976 Performance Stock Units (PSUs), indicating achievement of specific company performance targets.
- The vesting of these PSUs increases the CEO's direct ownership in the company, further aligning executive incentives with shareholder interests.
Future Outlook
60% of the Performance Stock Units acquired by the CEO are subject to time-based vesting and are scheduled to vest on October 1, 2026, contingent upon continued service to the company.
Industry Context
This filing is a routine disclosure of an insider transaction, specifically the vesting of performance-based equity awards for the CEO. It reflects executive compensation practices and the alignment of management incentives with company performance, rather than broader industry trends or competitive dynamics.
Stakeholder Impact
- Shareholders: The vesting of PSUs for the CEO indicates that performance targets were met, which could be viewed positively as it aligns executive incentives with shareholder value. It also increases the CEO's direct ownership, further aligning interests.
- Employees: The structure of executive compensation, including performance-based awards, can influence overall company culture and compensation strategies.
Next Steps
- 60% of the acquired Performance Stock Units (PSUs) will vest on October 1, 2026, subject to Emily M. Leproust's continued service.
Key Dates
| Date | Description |
|---|---|
| 09/01/2016 | 25% of shares subject to an employee stock option vested, with 1/48th vesting monthly thereafter. |
| 09/28/2017 | 10% of shares subject to an employee stock option vested, with 1/48th vesting monthly thereafter. |
| 09/28/2018 | 15% of shares subject to an employee stock option vested, with 1/48th vesting monthly thereafter. |
| 09/01/2020 | Performance stock options granted to the reporting person. |
| 10/24/2020 | 25% of shares subject to an employee stock option vested, with 1/48th vesting monthly thereafter. |
| 10/31/2019 | 20% of shares subject to an employee stock option vested, with 1/60th vesting monthly thereafter. |
| 12/19/2022 | Performance stock options (64,950 shares) vested and became exercisable as applicable performance criteria were met. |
| 09/28/2025 | Expiration date for an employee stock option with an exercise price of $5.95. |
| 10/28/2025 | Target criteria for Performance Stock Units (PSUs) were met, leading to the acquisition of 168,976 shares of common stock. |
| 10/30/2025 | Filing date of the Form 4. |
| 10/01/2026 | 60% of the acquired Performance Stock Units (PSUs) are scheduled to vest, subject to continued service. |
| 09/28/2027 | Expiration date for an employee stock option with an exercise price of $8.82. |
| 11/18/2028 | Expiration date for an employee stock option with an exercise price of $26.66. |
| 10/23/2029 | Expiration date for an employee stock option with an exercise price of $23.33. |
| 08/31/2030 | Expiration date for an employee stock option with an exercise price of $67.85. |
Recommendation
holdThis Form 4 filing details a routine insider transaction where the CEO acquired shares through the vesting of performance stock units. This indicates that pre-set performance targets were met, which is a positive sign for the company's operational execution and executive alignment. However, it does not provide new fundamental information about the company's financial health, strategic direction, or market position that would warrant a change in investment recommendation. It primarily reflects executive compensation and alignment of interests, suggesting no immediate catalyst for a 'buy' or 'sell' decision based solely on this filing.
Keywords
Twist Bioscience, TWST, Emily Leproust, CEO, Insider Transaction, Form 4, Stock Acquisition, Performance Stock Units, PSU, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.